Trial · NCT07912450
Study on the Efficacy and Safety of Non-Invasive Brain-Computer Interface With MRI-Guided Multi-Channel Time-Domain Interference Stimulation in Treating Motor Dysfunction in Acute Cerebral Infarction Patients
NCT07912450, Not applicable, Enrolling by invitation, The First Affiliated Hospital of Bengbu Medical University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study on the Efficacy and Safety of Non-Invasive Brain-Computer Interface With MRI-Guided Multi-Channel Time-Domain Interference Stimulation in Treating Motor Dysfunction in Acute Cerebral Infarction Patients. Trials, record NCT07912450. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912450
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Study on the Efficacy and Safety of Non-Invasive Brain-Computer Interface With MRI-Guided Multi-Channel Time-Domain Interference Stimulation in Treating Motor Dysfunction in Acute Cerebral Infarction Patients
- NCT number
- NCT07912450
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 378 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Bengbu Medical University
- Conditions
- Acute Ichemic Stroke
- Interventions
- Transcranial Temporal Interference Stimulation (tTIS), Sham tTIS
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects with modified Rankin Scale (mRS) score of 0-2 at 90 days | 90 days (± 4 days) after randomization | To evaluate the neurological recovery of subjects at 90 days after randomization. The modified Rankin Scale (mRS) will be used for assessment. The mRS score ranges from 0 to 6, where 0 indicates no symptoms, 1 indicates no significant disability, and 2 indicates slight disability but able to look after own affairs without assistance. This outcome measure defines an mRS score of 0-2 as a good functional outcome (functional independence), and the proportion of subjects achieving an mRS score of 0-2 will be calculated. |
| Secondary | Distribution of modified Rankin Scale (mRS) scores at 90 days after randomization | 90 days (± 4 days) after randomization | To evaluate the overall distribution of neurological disability in subjects at 90 days after randomization. The modified Rankin Scale (mRS) will be used, with scores ranging from 0 to 6. This outcome measure will summarize and report the number and proportion of subjects in each mRS score category (0, 1, 2, 3, 4, 5, 6). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33157010 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912450
GET https://conductscience.org/api/trials/v1/NCT07912450/registered